Nuvation Bio CRO exercises options, sells 63K shares

Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised stock options and sold shares in the company.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised stock options and sold shares in the company. Wentworth exercised options to acquire 63,000 shares of Class A common stock at an exercise price of $2.93 per share, then sold 63,000 shares in an open-market transaction at a weighted-average price of $6.0189 per share. The sales were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. Following these transactions, Wentworth directly holds 53,000 shares of Class A common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 63,000 shares ($195K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Wentworth Kerry

Role CHIEF REGULATORY OFFICER

Sold 63,000 shs ($379K)

Approx. gross sale proceeds $379K

Approx. exercise cost $185K

Approx. pre-tax spread $195K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	63,000	$0.00	$0.00
Exercise	Class A Common Stock	63,000	$2.93	$185K
Sale	Class A Common Stock	63,000	$6.0189	$379K

Holdings After Transaction: Stock Option (Right to Buy) — 152,250 contracts (Direct); Class A Common Stock — 53,000 shares (Direct)

Footnotes (3)

F1. Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
F2. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.08. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3. Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

Key Figures

Shares sold: 63,000 shares Sale price: $6.0189 per share Option exercise size: 63,000 shares +2 more

5 metrics

Shares sold 63,000 shares Class A Common Stock sold in open market on June 23, 2026

Sale price $6.0189 per share Weighted-average sale price, range $6.00 to $6.08

Option exercise size 63,000 shares Shares acquired via stock option exercise

Option exercise price $2.93 per share Exercise price for Stock Option (Right to Buy)

Post-transaction holdings 53,000 shares Direct Class A Common Stock held after transactions

Key Terms

Rule 10b5-1 plan, weighted-average sales price, Stock Option (Right to Buy)

3 terms

Rule 10b5-1 plan regulatory

"Shares sold pursuant to a 10b5-1 plan dated December 4, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted-average sales price financial

"Price reported is a weighted-average sales price. The shares were sold at prices ranging"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of $2.93 per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NUVB’s Kerry Wentworth report?

Kerry Wentworth reported exercising options for 63,000 Nuvation Bio shares and selling 63,000 shares in an open-market transaction at a weighted-average price of $6.0189 per share, according to a Form 4 insider trading report.

At what prices did the NUVB insider exercise and sell shares?

The NUVB insider exercised stock options at $2.93 per share and sold 63,000 Class A common shares at a weighted-average price of $6.0189, with individual sale prices ranging from $6.00 to $6.08, based on the filing’s transaction details.

How many NUVB shares does Kerry Wentworth own after the Form 4 transactions?

After the reported transactions, Kerry Wentworth directly holds 53,000 shares of Nuvation Bio Class A common stock. This figure reflects holdings following the same-day option exercise and open-market sale disclosed in the Form 4 filing.

Was the NUVB insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnotes state that the 63,000 Nuvation Bio shares were sold pursuant to a Rule 10b5-1 trading plan dated December 4, 2025, indicating the transactions were pre-arranged rather than timed discretionarily.

What type of derivative security did the NUVB insider exercise?

The insider exercised a “Stock Option (Right to Buy)” covering 63,000 shares of Nuvation Bio Class A common stock at an exercise price of $2.93 per share, as disclosed in the derivative transaction section of the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/24/2026 - 07:07 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wentworth Kerry

(Last)

(First)

(Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK

10036

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF REGULATORY OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	06/23/2026		M		63,000	A	$2.93	116,000	D
Class A Common Stock	06/23/2026		S⁽¹⁾		63,000	D	$6.0189⁽²⁾	53,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.93	06/23/2026		M			63,000	⁽³⁾	08/28/2032	Class A Common Stock	63,000	$0	152,250	D

Explanation of Responses:

1. Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.

2. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.08. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

3. Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR